The Pritzker School of Medicine is the M.D.-granting unit of the Biological Sciences Division of the University of Chicago. It is located on the university's main campus in the historic Hyde Park neighborhood of Chicago and matriculated its first class in 1927. The medical school offers a full-time Doctor of Medicine degree program, joint degree programs, graduate medical education, and continuing medical education.
Complete mesocolic excision (CME) is a surgical approach for right-sided colon cancer, involving the resection of the primary tumour along with an intact mesocolon, central vascular ligation, and exposure of the superior mesenteric vein. It has been postulated to improve oncologic outcomes such as disease-free survival and reduce local recurrence compared to standard right colectomy. However, the clinical benefits are still debated. This systematic review and meta-analysis, sponsored by the European Association for Endoscopic Surgery, aims to compare the oncologic outcomes of CME with standard right colectomy for right-sided colon cancer, with the ultimate objective to inform clinical practice recommendations. We followed the PRISMA 2020 reporting standards. A comprehensive literature search was conducted to identify relevant studies published from 2008 onwards, focusing on randomised trials and matched cohort studies comparing CME with standard right hemicolectomy. The GRADE methodology was used to assess the certainty of evidence, and minimal important differences were calculated to inform clinical relevance. Thirteen studies, amongst which three randomised trials, were included. No difference was found between CME and standard colectomy in terms of 30-day mortality, major peri-operative morbidity, or major blood loss. However, patients who underwent CME showed improved overall survival (HR = 0.67, 95
Cancer constitutes one of the most urgent global health crises, with over 20 million new cases diagnosed annually worldwide, claiming 10 million lives. This devastating burden disproportionately affects vulnerable populations: 75% of cancer deaths occur in low- and middle-income countries despite these regions having lower reported incidence rates. Lung cancer leads the global toll, representing 12% of all cases but 19% of deaths, followed by breast cancer (12% of cases) and colorectal cancer (9.6%). A stark geographical inequity defines the cancer landscape-while wealthy regions such as North America, Northern Europe and Australia report the highest incidence rates, Africa and Latin America suffer the highest mortality rates. This disparity will intensify dramatically: cancer deaths in low-income countries are projected to surge 155% compared to just 56% in high-income nations by 2050. The financial devastation compounds this crisis, with 56% of patients worldwide facing catastrophic health expenditures extending beyond medical costs to include lost income and reduced productivity. Economic burden varies starkly by wealth: 75% of patients in low-income countries experience financial catastrophe versus 58% in middle-income countries and 26% in high-income nations. However, cancer prevention offers unprecedented opportunities to transform this crisis through interventions we already possess. From largely preventable infectious cancers like stomach and cervical malignancies, to lifestyle-driven epidemics including lung and colorectal cancers, to complex multifactorial diseases like breast cancer. Evidence-based prevention strategies can dramatically reduce suffering while generating massive healthcare savings. Emerging genetic technologies amplify this potential: universal genetic testing and pharmacogenomics now enable identification of high-risk individuals before disease develops, allowing targeted prevention while optimising treatments based on individual genetic profiles. Cancer prevention represents not merely a health opportunity but an economic imperative. The primary barrier is no longer scientific understanding but systematic implementation. Governments, policymakers, insurance companies and the public urgently need clearer evidence and education demonstrating proven successes to motivate decisive action toward creating healthier populations and reducing cancer burdens worldwide.
In recent years, higher rates of overdose deaths have been observed among Black individuals in the United States compared to individuals who are white or other races, as part of the potent fourth wave of the opioid epidemic. However, much of the research addressing this surge has focused on Black individuals in urban areas, despite evidence that usage and overdose rates are accelerating among rural Black People Who Use Drugs (PWUD), a gap we aim to fill here via a qualitative assessment. Between September 2023 and June 2024, we conducted semi-structured interviews with a sample of Black adult PWUD who live in rural southern Illinois. The interviews were evaluated using abductive analytic methods. In general, participants highlighted exposure to parental substance use and poor mental health as key factors contributing to drug use initiation. Participants further described their social networks as small, emphasizing a desire to stay hidden to avoid social scrutiny. Finally, participants had mixed feelings about the nature and value of medications for opioid use disorder (e.g., buprenorphine, methadone, etc.) and expressed limited knowledge about where to access harm reduction resources like naloxone. Rural Black PWUD may experience complex early-life exposures to substance use and later-life challenges in terms of communal integration due to stigma and structural disenfranchisment. These dynamics may specifically prevent the manifestation of strong support networks and engagement with treatment and harm reduction.
This JAMA Clinical Guidelines Synopsis summarizes the 2024 Canadian Research Initiative in Substance Matters (CRISM) guideline on management of opioid use disorder (OUD).